Jeremie Vitte
Affiliations: | University of California, Los Angeles, Los Angeles, CA |
Area:
Neuro-oncologyGoogle:
"Jeremie Vitte"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Judith Melki | grad student | ||
| Alexis Brice | post-doc | ||
| Marco Giovannini | research scientist |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Nghiemphu PL, Vitte J, Dombi E, et al. (2024) Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma. Journal of Neuro-Oncology |
| Staedtke V, Anstett K, Bedwell D, et al. (2023) Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials. Clinical Trials (London, England). 17407745231207970 |
| Chiasson-MacKenzie C, Vitte J, Liu CH, et al. (2023) Cellular mechanisms of heterogeneity in NF2-mutant schwannoma. Nature Communications. 14: 1559 |
| Roberts DS, Maurya R, Takemon Y, et al. (2019) Linked-read Sequencing Analysis Reveals Tumor-specific Genome Variation Landscapes in Neurofibromatosis Type 2 (NF2) Patients. Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 40: e150-e159 |
| Fuse MA, Dinh CT, Vitte J, et al. (2019) Preclinical Assessment of MEK1/2 Inhibitors for Neurofibromatosis Type 2-Associated Schwannomas Reveal Differences in Efficacy and Drug Resistance Development. Neuro-Oncology |
| Osum S, Stemmer-Rachamimov A, Widemann B, et al. (2019) TMOD-23. PRECLINICAL DRUG EVALUATION IN A GENETICALLY ENGINEERED MINIPIG MODEL OF NEUROFIBROMATOSIS TYPE 1 Neuro-Oncology. 21: vi267-vi267 |
| Vitte J, Gao F, Coppola G, et al. (2019) TMOD-15. SPATIOTEMPORAL LOSS OF SMARCB1 IN EARLY NEURAL CREST LINEAGE LEADS TO DIFFERENT MOLECULAR SUBTYPES OF RHABDOID TUMORS Neuro-Oncology. 21: ii124-ii124 |
| Isakson SH, Rizzardi AE, Coutts AW, et al. (2018) Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1. Communications Biology. 1: 158 |
| Paganini I, Capone GL, Vitte J, et al. (2017) Double somatic SMARCB1 and NF2 mutations in sporadic spinal schwannoma. Journal of Neuro-Oncology |
| Vitte J, Gao F, Coppola G, et al. (2017) Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development. Nature Communications. 8: 300 |